<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">32643</article-id><article-id pub-id-type="doi">10.17116/terarkh2016881042-45</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Editorial article</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Передовая статья</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Latent autoimmune diabetes of adults (LADA): The informative value of autoantibodies</article-title><trans-title-group xml:lang="ru"><trans-title>Латентный аутоиммунный диабет взрослых: информативность аутоантител</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Silko</surname><given-names>Yu V</given-names></name><name xml:lang="ru"><surname>Силко</surname><given-names>Ю В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nikonova</surname><given-names>T V</given-names></name><name xml:lang="ru"><surname>Никонова</surname><given-names>Т В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ivanova</surname><given-names>O N</given-names></name><name xml:lang="ru"><surname>Иванова</surname><given-names>О Н</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Stepanova</surname><given-names>S M</given-names></name><name xml:lang="ru"><surname>Степанова</surname><given-names>С М</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Shestakova</surname><given-names>M V</given-names></name><name xml:lang="ru"><surname>Шестакова</surname><given-names>М В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Dedov</surname><given-names>I I</given-names></name><name xml:lang="ru"><surname>Дедов</surname><given-names>И И</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">Эндокринологический научный центр Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2016-10-15" publication-format="electronic"><day>15</day><month>10</month><year>2016</year></pub-date><volume>88</volume><issue>10</issue><issue-title xml:lang="en">VOL 88, NO10 (2016)</issue-title><issue-title xml:lang="ru">ТОМ 88, №10 (2016)</issue-title><fpage>42</fpage><lpage>45</lpage><history><date date-type="received" iso-8601-date="2020-04-11"><day>11</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2016, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2016, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/32643">https://ter-arkhiv.ru/0040-3660/article/view/32643</self-uri><abstract xml:lang="en"><p>Aim. To investigate the prevalence of autoantibodies (autoAbs) associated with the development of type 1 diabetes mellitus (T1DM) in latent autoimmune diabetes of adults (LADA) in the Russian Federation. Subjects and methods. A total of 96 patients (46 women and 50 men) with LADA were examined. All the patients underwent an immunological examination including the determination of autoAbs, such as glutamic acid decarboxylase autoAbs (GADA), islet antigen-2 auto-Abs (IA-2A), islet cell cytoplasmic auto-Abs (ICA), zinc transporter 8 auto-Abs (ZnT8A), and insulin auto-Abs (IAA). Results. GADAs were found in 61.5% of the examinees. ICAs were detected in 24%, IA-2As were observed in 57.3%. AutoAbs were more frequently observed in combination than alone. IAAs were least commonly seen in 8.3% and only in combinations. ZnT8As were found in 52.1% of the examinees and they were present alone in 5.2%. Conclusion. The antibodies that are most frequently observed in LADA are GADAs, IA-2As and ZnT8As. It is insufficient to identify only GADAs, as the latter are found in only 61.5% of the patients. IA-2As and ZnT8As, which are present in 57.3% and 52.1% of the patients, respectively, should also be used in the diagnosis of LADA. ICAs are much less commonly seen and along with IAAs may be additional markers for LADA.</p></abstract><trans-abstract xml:lang="ru"><p>Резюме Цель исследования. Изучить распространенность аутоантител (аутоАТ), ассоциированных с развитием сахарного диабета 1-го типа (СД-1) при латентном аутоиммунном диабете взрослых (LADA) в Российской Федерации. Материалы и методы. Обследовали 96 пациентов (46 женщин и 50 мужчин) с LADA. Всем пациентам выполнено иммунологическое исследование, включавшее определение аутоАТ GADA, IA-2A, ICA, ZnT8A, IAA. Результаты. У 61,5% обследованных определили GADA. ICA выявлены у 24%, IA-2A — у 57,3%. AутоАТ встречались в комбинации чаще, чем изолированно. Реже всего встречались IAA — у 8,3% и только в комбинациях. АутоАТ ZnT8A обнаружены у 52,1 % обследованных, у 5,2% обследованных они определялись изолированно. Заключение. Наиболее часто встречающимися при LADA являются аутоАТ GADA, IA-2A и ZnT8. Определение только GADA является недостаточным, так как они обнаруживаются лишь у 61,5% пациентов. IA-2A и ZnT8A, встречающиеся у 57,3 и 52,1 % пациентов соответственно, также должны применяться в диагностике LADA. ICA встречаются значительно реже, и наряду с IAA могут быть дополнительными маркерами LADA.</p></trans-abstract><kwd-group xml:lang="en"><kwd>diabetes mellitus</kwd><kwd>latent autoimmune diabetes of adults</kwd><kwd>islet cell cytoplasmic autoantibodies</kwd><kwd>islet antigen-2 autoantibodies</kwd><kwd>glutamic acid decarboxylase autoantibodies</kwd><kwd>zinc transporter 8 autoantibodies</kwd><kwd>LADA</kwd><kwd>ICA</kwd><kwd>IA-2A</kwd><kwd>GADA</kwd><kwd>ZnT8</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>сахарный диабет</kwd><kwd>латентный аутоиммунный диабет взрослых</kwd><kwd>аутоантитела к транспортеру цинка Т8</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Basile K, Guy V, Schwartz S, Grant S. Overlap of Genetic Susceptibility to type 1 diabetes, type 2 diabetes, and Latent Autoimmune Diabetes in Adults. Curr Diab Report. 2014;14:550. doi:10.1007/s11892-014-0550-9</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Laugesen E, Ostergaard JA, Leslie RDG. Latent autoimmune diabetes of the adults: current knowledge and uncertainty. Diabet Med. 2015l;32(7):843-852. doi:10.1111/dme.12700</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Дедов И.И., Шестакова М.В., Кураева Т.Л., Титович Е.В., Никонова Т.В. Нозологическая гетерогенность, молекулярная генетика и иммунология аутоиммунного сахарного диабета. Вестник РАМН. 2015;2:189-195.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Tuomi T, Santoro N, Caprio S, Cai M et al. The many faces of diabetes: a disease with increasing heterogeneity. Lancet. 2014;383:1084-1094. doi:10.1016/S0140-6736(13)62219-9</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Liao Y, Xiang Y, Zhou Z. Diagnostic criteria of latent autoimmune diabetes in adults (LADA): a review and reflection. Front Med. 2012;6(3):243-247. doi:10.1007/s11684-012-0201-y</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Wenzlau JM, Juhl K, Yu L, Moua O et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human 1 type diabetes. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(43):17040-17045. doi:10.1073/pnas.0705894104</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Delitala AP, Pes GM, Fanciulli G, Maioli M et al. Organ-specific antibodies in LADA patients for the prediction of insulin dependence. Endocrine Res. 2016;11:1-6. doi:10.3109/07435800.2015.1136934</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Zhou Z, Xiang Y, Ji L, Jia W et al. Frequency, Immunogenetics, and Clinical Characteristics of Latent Autoimmune Diabetes in China (LADA China Study). Diabetes. 2013;62:543-550. doi:10.2337/db12-0207</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Hawa MI, Kolb H, Schloot N, Beyan H et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: action LADA 7. Diabetes Care. 2013;36:908-913. doi:10.2337/dc12-0931</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Xiang Y, Huang G, Shan Z, Pan L, Luo S et al. Glutamic acid decarboxylase autoantibodies are dominant but insufficient to identify most Chinese with adult-onset non-insulin requiring autoimmune diabetes: LADA China study 5. Acta Diabetologica. 2015;52:1121-1127. doi:10.1007/s00592-015-0799-8</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Lampasona V, Petrone A, Tiberti C et al. Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: Non Insulin Requiring Autoimmune Diabetes (NIRAD) 4. Diabetes Care. 2010;33:104-108. doi:10.2337/dc08-2305</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Trabucchi A, Faccinetti NI, Guerra LL, Puchulu FM et al. Detection and characterization of ZnT8 autoantibodies could help to screen latent autoimmune diabetes in adult-onset patients with type 2 phenotype. Autoimmunity. 2012;45(2):137-142. doi:10.3109/08916934.2011.604658</mixed-citation></ref></ref-list></back></article>
